###### Key messages

What is already known about this subject?
=========================================

-   The efficacy and safety of tofacitinib in patients with rheumatoid arthritis (RA) have been demonstrated previously in Phase II and Phase III clinical trials of up to 24 months' duration and in long-term extension studies with up to 114 months of observation.

-   Elevated levels of rheumatoid factor (RF) and/or anticyclic citrullinated peptide (CCP) antibodies (seropositivity) are common in patients with RA and may indicate greater disease severity, a higher risk of disease progression and may influence responses to treatments for RA.

What does this study add?
=========================

-   In a posthoc, pooled analysis of five Phase III studies, tofacitinib 5 or 10 mg two times a day significantly improved ACR20/50/70 response rates, DAS28-4(ESR) low disease activity (LDA) rates and change from baseline in Health Assessment Questionnaire-Disability Index and Functional Assessment of Chronic Illness Therapy-Fatigue vs placebo in patients with seropositive or seronegative RA.

-   Patients who were anti-CCP+/RF+ were more likely to achieve ACR20/50/70 responses with tofacitinib than anti-CCP-/RF- patients (ACR20/50: both tofacitinib doses; ACR70: tofacitinib 10 mg two times a day); anti-CCP+/RF+ or anti-CCP+/RF- patients receiving tofacitinib 10 mg two times a day were more likely to achieve DAS28-4(ESR) remission or LDA than anti-CCP-/RF- patients.

How might this impact on clinical practice?
===========================================

-   This study adds to the collective evidence on the relationship between seropositivity and the efficacy of tofacitinib, which may help to inform future therapeutic strategies.

Introduction {#s1}
============

Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease that has a major effect on health status and quality of life.[@R1] RA is characterised by inflammation of the articular synovium leading to deformity, progressive disability and ultimately destruction of joints.

The current guidelines of both the European League against Rheumatism and the American College of Rheumatology (ACR) recommend a 'treat-to-target' approach, with the primary goals of treating patients with RA identified as the attainment of remission or low disease activity (LDA) if remission is not achievable.[@R3] The use of the conventional synthetic (cs) disease-modifying antirheumatic drug (DMARD) methotrexate (MTX) in conjunction with glucocorticoids (GC), either as monotherapy or in combination with other csDMARDs, is recommended as first-line therapy, with the aim of target attainment by 6 months. If this treatment fails, or if unfavourable prognostic markers such as early erosions, autoantibodies or high disease activity are present, the addition of other csDMARDs, biologic DMARDs or targeted synthetic DMARDs is recommended.[@R3] However, clinical outcomes of current treatments remain variable.

Conflicting efficacy results have been observed for tumour necrosis factor inhibitors (TNFi) in different studies. Previously, a randomised double-blind study of etanercept in combination with MTX resulted in 85% of patients achieving a 20% improvement in RA according to ACR criteria (ACR20 response).[@R5] However, an earlier study investigating the same treatment regimen reported an ACR20 response rate of 71%.[@R6] Furthermore, contrasting results have also been observed in different studies of infliximab. While one study from 2000 found ACR20 responses in 42% of patients following treatment with infliximab in combination with MTX,[@R7] other, more recent studies with the same treatments resulted in ACR20 responses in 62.4%,[@R8] 60%[@R9] and 58.6%[@R10] of patients. Therefore, gaining a better understanding of the underlying differences in patient characteristics that give rise to variation in response to treatment would be of benefit and would allow the identification of patient subpopulations most likely to respond to specific treatment modalities.

Elevated levels of rheumatoid factor (RF) and/or anticyclic citrullinated peptide (CCP) antibodies (seropositivity) are common in patients with RA and it has been estimated that approximately 80% and 70% are seropositive for RF and CCP, respectively.[@R11] Anti-CCP and/or RF seropositivity can occur several years before the onset of RA[@R13] and may indicate greater disease severity and a higher risk of disease progression than seronegativity.[@R14] It is possible that anti-CCP and/or RF seropositivity could influence responses to treatments for RA, therefore investigation of the relationship between these markers and treatment efficacy may help to inform future therapeutic strategies. However, assessment of RF or anti-CCP seropositivity as individual diagnostic markers has been questioned due to the moderate sensitivity of serological tests.[@R18] An alternative diagnostic approach involving analysis of RF+ and CCP+ in combination has been suggested as a more effective prognostic indicator of structural damage early in the course of the disease than detection of individual markers.[@R20]

Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of RA. The efficacy and safety of tofacitinib 5 and 10 mg two times a day administered as monotherapy or in combination with csDMARDs, mainly MTX, in patients with moderately to severely active RA, have been demonstrated in Phase II[@R21] and Phase III randomised controlled trials of up to 24 months' duration[@R28] and in long-term extension studies with up to 114 months of observation.[@R34]

This posthoc subgroup analysis used pooled data from five Phase III studies of tofacitinib to examine treatment response in patients with seropositive vs seronegative RA.

Methods {#s2}
=======

Clinical trials {#s2-1}
---------------

Subgroup data were pooled across five Phase III randomised, placebo-controlled, double-blind studies of 6 to 24 months' duration. Tofacitinib was administered at 5 or 10 mg two times a day, either as monotherapy (ORAL Solo, ClinicalTrials.gov number: NCT00814307)[@R29] or in combination with csDMARDs, mainly MTX (ORAL Sync: NCT00856544;[@R30] ORAL Standard: NCT00853385;[@R33] ORAL Scan: NCT00847613[@R32] and ORAL Step: NCT00960440[@R28]) in patients with moderately to severely active RA and an inadequate response to ≥1 csDMARD or biologic DMARD. One Phase III study (ORAL Standard) included an active comparator of adalimumab (40 mg subcutaneously once every 2 weeks). Patients were permitted stable background doses of low-dose oral GCs and non-steroidal anti-inflammatory drugs.

Serotype subgroups {#s2-2}
------------------

The seropositivity status of each patient was recorded at baseline. For this analysis, patients were categorised as: anti-CCP and RF positive (anti-CCP+/RF+); anti-CCP+/RF negative (-); anti-CCP-/RF+; anti-CCP-/RF-.

Efficacy endpoints and patient-reported outcomes {#s2-3}
------------------------------------------------

The following efficacy endpoints were evaluated at month 3 in patients receiving tofacitinib 5 or 10 mg two times a day or placebo for each serotype subgroup: proportions of patients achieving ACR20/50/70 response (defined as 20%, 50% or 70% improvement in ACR criteria, respectively) and Disease Activity Score in 28 joints, erythrocyte sedimentation rate (DAS28-4\[ESR\])-defined remission (\<2.6) and LDA (≤3.2). Patient-reported outcomes (PROs) were also evaluated at month 3 and included changes from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI), Short Form-36 Health Survey (SF-36) physical functioning domain and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).

Safety endpoints {#s2-4}
----------------

Safety was assessed based on reporting of treatment-emergent adverse events (TEAEs), serious AEs (SAEs), discontinuations due to AEs, serious infections, herpes zoster infections, malignancies (excluding non-melanoma skin cancer \[NMSC\]) and NMSC.

Statistical analyses {#s2-5}
--------------------

Posthoc efficacy and PRO analyses were based on the full analysis set, which included all patients who received at least one dose of study drug and for whom data were available from at least one postbaseline assessment.

Binary endpoints were compared between the tofacitinib 5 mg two times a day, tofacitinib 10 mg two times a day and placebo groups using the normal approximation to the binomial distribution, with non-responder imputation for missing values. In order to compare efficacy between seropositive and seronegative subgroups, Cochran-Mantel-Haenszel adjusted ORs with upper and lower 95% CIs were calculated for ACR20, ACR50 and ACR70 response rates and for DAS28-4(ESR) remission and LDA rates at month 3.

Continuous endpoints were analysed using a linear mixed-effects model for repeated measures. Estimates of mean changes from baseline for each treatment, as well as differences in means vs placebo, were derived from the model as least squares means (LSM), with corresponding 95% CIs. All statistical comparisons were considered exploratory with no adjustment for multiplicity.

The impact of seropositivity status and smoking status on the rate of DAS28-4(ESR) remission and LDA at month 3 was assessed by logistic regression analysis ([online supplementary material 1](#SP1){ref-type="supplementary-material"}).
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Safety endpoints were reported throughout the duration of each study and were based on all treated patients who received at least one dose of study drug. Incidence rates (IR; unique patients with events per 100 patient-years \[PY\] of observation) were calculated for discontinuations due to AEs, serious infections and herpes zoster events; 95% CIs for IRs were based on maximum likelihood estimation.

Results {#s3}
=======

Patient demographics and baseline characteristics {#s3-1}
-------------------------------------------------

This posthoc analysis pooled data from 3061 patients. Of these, 1194 received tofacitinib 5 mg two times a day, 1197 received tofacitinib 10 mg two times a day and 670 received placebo. Demographics and baseline characteristics were generally similar across treatment groups and across serotype subgroups (anti-CCP+/RF+, n=1961 across all treatment groups; anti-CCP+/RF-, n=337 across all treatment groups; anti-CCP-/RF+, n=182 across all treatment groups; anti-CCP-/RF-, n=581 across all treatment groups; [table 1](#T1){ref-type="table"}).

###### 

Patient demographics and baseline characteristics

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                     Tofacitinib 5 mg two times a day\   Tofacitinib 10 mg two times a day\   Placebo\                                                                                                                               
                                     N=1194                              N=1197                               N=670                                                                                                                                  
  ---------------------------------- ----------------------------------- ------------------------------------ -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  Median age, years (range)          54.0\                               53.0\                                53.0\          53.0\          54.0\          54.0\          53.0\          54.0\          54.0\          47.5\          52.5\          53.0\
                                     (20.0--86.0)                        (20.0--82.0)                         (25.0--79.0)   (18.0--83.0)   (18.0--85.0)   (20.0--78.0)   (28.0--76.0)   (19.0--78.0)   (18.0--82.0)   (18.0--80.0)   (34.0--74.0)   (29.0--79.0)

  Female, n (%)\*                    651 (83.9)                          120 (88.2)                           62 (83.8)      177 (85.1)     650 (83.9)     99 (87.6)      62 (91.2)      205 (85.1)     326 (79.5)     74 (84.1)      34 (85.0)      109 (82.6)

  Smoking status, n (%)\*                                                                                                                                                                                                                            

   Never smoked                      492 (63.4)                          107 (78.7)                           52 (70.3)      144 (69.2)     485 (62.6)     87 (77.0)      48 (70.6)      175 (72.6)     252 (61.6)     59 (67.8)      26 (65.0)      81 (61.4)

   Smoker                            114 (14.7)                          11 (8.1)                             9 (12.2)       28 (13.5)      153 (19.7)     8 (7.1)        11 (16.2)      39 (16.2)      79 (19.3)      13 (14.9)      10 (25.0)      25 (18.9)

   Ex-smoker                         170 (21.9)                          18 (13.2)                            13 (17.6)      36 (17.3)      137 (17.7)     18 (15.9)      9 (13.2)       27 (11.2)      78 (19.1)      15 (17.2)      4 (10.0)       26 (19.7)

  BMI mean (range)                   26.6\                               26.0\                                27.7\          29.2\          26.8\          25.8\          28.1\          28.4\          26.9\          25.1\          28.3\          29.5\
                                     (14.3--70.3)                        (17.5--49.7)                         (16.7--52.1)   (16.0--70.8)   (14.4--55.6)   (15.6--44.4)   (16.3--58.1)   (17.1--50.2)   (16.0--55.1)   (15.4--50.4)   (17.5--45.9)   (14.7--53.8)

  Duration of RA, years, mean (SD)   9.4 (8.0)                           9.3 (8.5)                            7.6 (7.4)      6.7 (7.6)      9.7 (8.3)      8.4 (8.6)      9.6 (8.4)      7.6 (7.5)      9.9 (8.6)      6.6 (6.4)      11.9 (8.4)     8.4 (8.9)

  DAS28-4(ESR), mean (SD)            6.5 (1.0)                           6.2 (0.9)                            6.3 (0.9)      6.5 (1.0)      6.5 (1.0)      6.1 (0.9)      6.4 (1.0)      6.4 (1.0)      6.5 (0.9)      6.1 (0.9)      6.2 (1.1)      6.4 (1.0)

  HAQ-DI, mean (SD)                  1.5 (0.7)                           1.4 (0.6)                            1.4 (0.7)      1.5 (0.6)      1.5 (0.7)      1.2 (0.6)      1.4 (0.7)      1.5 (0.6)      1.5 (0.7)      1.3 (0.7)      1.4 (0.7)      1.4 (0.6)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Percentages are based on patients with non-missing values.

BMI, body mass index; CCP, cyclic citrullinated peptide; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; HAQ‑DI, Health Assessment Questionnaire-Disability Index; RA, rheumatoid arthritis; RF, rheumatoid factor.

ACR20/50/70 response rates {#s3-2}
--------------------------

At month 3, ACR20/50/70 response rates were significantly higher among patients receiving tofacitinib 5 and 10 mg two times a day compared with placebo across all serotype subgroups (all p≤0.05 vs placebo; [figure 1](#F1){ref-type="fig"}). Patients who were anti-CCP+/RF+ and receiving tofacitinib 5 or 10 mg two times a day were more likely to achieve ACR20/50 responses than those on the same treatment who were anti-CCP-/RF-. Among patients treated with tofacitinib 10 mg two times a day, those who were anti-CCP+/RF+ were also more likely to achieve an ACR70 response than those who were anti-CCP-/RF-. Anti-CCP+/RF- and anti-CCP-/RF+ patients had similar odds of achieving ACR20/50/70 responses as anti-CCP-/RF- patients ([table 2](#T2){ref-type="table"}).

![The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day or placebo achieving (A) ACR20, (B) ACR50 and (C) ACR70 responses at month 3. For all endpoints, p≤0.05 with tofacitinib 5 and 10 mg two times a day compared with placebo across all serotype subgroups. All data shown are for the full analysis set. Missing data were imputed as non-response to treatment. ACR, American College of Rheumatology; BID, two times a day; CCP, cyclic citrullinated peptide; RF, rheumatoid factor.](rmdopen-2018-000742f01){#F1}

###### 

ORs (and 95% CIs) for seropositive vs seronegative groups for ACR50 and ACR70 response at month 3

  ------------------------------------------------------------------------------------------------
                                       Anti-CCP+/RF+ vs\   Anti-CCP+/RF- vs\   Anti-CCP-/RF+ vs\
                                       anti-CCP-/RF-       anti-CCP-/RF-       anti-CCP-/RF-
  ------------------------------------ ------------------- ------------------- -------------------
  ACR20                                                                        

   Tofacitinib 5 mg two times a day    2.0 (1.5 to 2.8)    1.3 (0.8 to 2.0)    1.2 (0.7 to 2.1)

   Tofacitinib 10 mg two times a day   2.2 (1.6 to 2.9)    1.6 (1.0 to 2.6)    1.2 (0.7 to 2.0)

   Placebo                             1.3 (0.8 to 2.1)    1.6 (0.9 to 3.0)    0.7 (0.3 to 1.8)

  ACR50                                                                        

   Tofacitinib 5 mg two times a day    1.9 (1.3 to 2.7)    1.3 (0.7 to 2.1)    1.3 (0.7 to 2.5)

   Tofacitinib 10 mg two times a day   1.9 (1.3 to 2.6)    1.4 (0.8 to 2.3)    1.5 (0.8 to 2.7)

   Placebo                             1.9 (0.9 to 4.1)    1.0 (0.3 to 3.1)    0.8 (0.2 to 3.9)

  ACR70                                                                        

   Tofacitinib 5 mg two times a day    1.6 (0.9 to 2.7)    0.7 (0.3 to 1.6)    1.4 (0.6 to 3.3)

   Tofacitinib 10 mg two times a day   2.2 (1.4 to 3.6)    1.5 (0.8 to 3.1)    2.0 (0.9 to 4.3)

   Placebo                             1.4 (0.4 to 5.0)    0.5 (0.1 to 5.0)    1.1 (0.1 to 10.7)

  DAS28-4(ESR) \<2.6                                                           

   Tofacitinib 5 mg two times a day    0.9 (0.4 to 1.7)    1.2 (0.5 to 2.9)    1.1 (0.4 to 3.4)

   Tofacitinib 10 mg two times a day   2.8 (1.3 to 5.8)    5.6 (2.3 to 13.3)   1.3 (0.3 to 4.9)

   Placebo                             0.6 (0.2 to 2.6)    0.6 (0.1 to 5.9)    1.2 (0.1 to 12.1)

  DAS28-4(ESR) ≤3.2                                                            

   Tofacitinib 5 mg two times a day    1.2 (0.7 to 1.9)    1.4 (0.7 to 2.6)    1.2 (0.5 to 2.7)

   Tofacitinib 10 mg two times a day   1.8 (1.1 to 2.9)    3.2 (1.7 to 5.8)    1.7 (0.8 to 3.7)

   Placebo                             2.2 (0.6 to 7.5)    0.6 (0.1 to 5.9)    1.2 (0.1 to 12.1)
  ------------------------------------------------------------------------------------------------

ACR20/50/70, ≥20/50/70% improvement in American College of Rheumatology criteria; CCP, cyclic citrullinated peptide; CMH, Cochran-Mantel-Haenszel; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; RF, rheumatoid factor.

DAS28-4(ESR) response rates {#s3-3}
---------------------------

In anti-CCP+/RF+ and anti-CCP+/RF- patients, significantly higher rates of DAS28-4(ESR) remission were achieved by those receiving tofacitinib compared with placebo (all p≤0.05 vs placebo; [figure 2A](#F2){ref-type="fig"}). In anti-CCP-/RF+ and anti-CCP-/RF- patients, DAS28-4(ESR) remission rates were numerically higher in those treated with tofacitinib 5 and 10 mg two times a day than in patients treated with placebo; however, these differences did not reach statistical significance ([figure 2A](#F2){ref-type="fig"}).

![The proportions (and 95% CIs) of anti-CCP+/RF+, anti-CCP+/RF- anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day or placebo achieving DAS28-4(ESR)-defined (A) remission (score \<2.6) and (B) LDA (score ≤3.2) at month 3. For DAS28-4(ESR)\<2.6, p≤0.05 with tofacitinib 5 and 10 mg two times a day compared with placebo in anti-CCP+/RF+, anti-CCP+/RF- subgroups. For DAS28-4(ESR)≤3.2, p≤0.05 with tofacitinib 5 and 10 mg two times a day compared with placebo across all serotype subgroups. BID, two times a day; CCP, cyclic citrullinated peptide; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; LDA, low disease activity; RF, rheumatoid factor.](rmdopen-2018-000742f02){#F2}

DAS28-4(ESR) LDA rates were significantly higher among patients receiving tofacitinib 5 or 10 mg two times a day compared with placebo across all serotype subgroups (all p≤0.05 vs placebo; [figure 2B](#F2){ref-type="fig"}).

Comparisons of seropositive and seronegative subgroups showed that patients who were anti-CCP+/RF+ or anti-CCP+/RF- and treated with tofacitinib 10 mg two times were more likely to achieve DAS28-4(ESR) remission or LDA than those on the same treatment who were anti-CCP-/RF- ([table 2](#T2){ref-type="table"}).

HAQ-DI, FACIT-F and SF-36 physical functioning domain {#s3-4}
-----------------------------------------------------

Patients receiving tofacitinib 5 or 10 mg two times a day reported significantly greater improvements from baseline in HAQ-DI compared with placebo across all serotype subgroups (all p≤0.05 vs placebo; [figure 3A](#F3){ref-type="fig"}).

![Least squares mean changes from baseline (and 95% CIs) at month three for (A) HAQ-DI, (B) FACIT-F and (C) SF-36 physical functioning domain observed in anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving tofacitinib 5 or 10 mg two times a day or placebo. for HAQ-DI and FACIT-F, p≤0.05 with tofacitinib 5 mg two times a day compared with placebo in anti-CCP+/RF+, anti-CCP+/RF- and anti-CCP-/RF+ subgroups and p≤0.05 with tofacitinib 10 mg two times a day compared with placebo across all serotype subgroups. for SF-36 physical functioning domain, p≤0.05 with tofacitinib 5 and 10 mg two times a day compared with placebo across all serotype subgroups. BID, two times a day; CCP, cyclic citrullinated peptide; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire-Disability index; LSM, least squares mean; RF, rheumatoid factor; SF-36, Short Form-36 Health Survey.](rmdopen-2018-000742f03){#F3}

Similarly, improvements from baseline in FACIT-F were significantly greater in patients receiving tofacitinib 5 or 10 mg two times a day compared with placebo across all serotype subgroups, (all p≤0.05 vs placebo; [figure 3B](#F3){ref-type="fig"}).

SF-36 physical functioning was significantly improved following treatment with tofacitinib 5 or 10 mg two times a day compared with placebo in patients who were anti-CCP+/RF+, anti-CCP+/RF- or anti-CCP-/RF+ (p≤0.05 vs placebo; [figure 3C](#F3){ref-type="fig"}). In the anti-CCP-/RF- subgroup, only patients receiving tofacitinib 10 mg two times a day reported significant improvements in the SF-36 physical functioning domain (p≤0.05); no significant improvement vs placebo was observed in anti-CCP-/RF- patients receiving tofacitinib 5 mg two times a day ([figure 3C](#F3){ref-type="fig"}).

Logistic regression analysis {#s3-5}
----------------------------

In separate models, where DAS28-4(ESR) remission or LDA were included as dependent variables and treatment, smoking status, seropositivity status and interaction between smoking status and seropositivity status groups as independent variables, there were no significant differences in remission or LDA, based on smoking status or the interaction between smoking status and seropositivity status. In another model with only treatment and seropositivity status groups as independent variables, significant differences in rates of DAS28-4(ESR) remission or LDA were observed with both doses of tofacitinib (5 and 10 mg two times a day), compared with placebo. In addition, there were significant differences in remission between anti-CCP+/RF- vs anti-CCP-/RF- subgroups, and significant differences in LDA between anti-CCP+/RF+ vs anti-CCP-/RF-, and anti-CCP+/RF- vs anti-CCP-/RF- subgroups ([online supplementary table 1](#SP1){ref-type="supplementary-material"}).

Safety {#s3-6}
------

Frequencies of AEs were similar across all treatment groups and serotype subgroups ([table 3](#T3){ref-type="table"}). Across serotype subgroups, TEAEs were observed in: 47.8%--54.3% of patients receiving tofacitinib 5 mg two times a day; 47.8%--57.4% of patients receiving tofacitinib 10 mg two times a day; and 50.2%--58.3% of patients receiving placebo. SAEs were observed in: 2.2%--3.5% of patients receiving tofacitinib 5 mg two times a day; 1.7%--4.4% of patients receiving tofacitinib 10 mg two times a day and 2.5%--5.7% of patients receiving placebo.

###### 

Safety endpoints across serotype subgroups for patients receiving tofacitinib or placebo

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *n (%)*\                        Tofacitinib 5 mg two times a day\   Tofacitinib 10 mg two times a day\   Placebo\                                                                                                                                                          
  *IR (95% CI)*                   N=1194                              N=1197                               N=670                                                                                                                                                             
  ------------------------------- ----------------------------------- ------------------------------------ ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- -----------------
  TEAEs                           393 (50.6)                          65 (47.8)                            39 (52.7)         113 (54.3)        417 (53.8)        54 (47.8)         39 (57.4)         125 (51.9)        206 (50.2)        46 (52.3)         23 (57.5)         77 (58.3)

  SAEs                            27 (3.5)                            3 (2.2)                              2 (2.7)           7 (3.4)           21 (2.7)          5 (4.4)           2 (2.9)           4 (1.7)           13 (3.2)          5 (5.7)           1 (2.5)           4 (3.0)

  Discontinuations due to AEs\*   77 (9.9)\                           11 (8.1)\                            8 (10.8)\         16 (7.7)\         77 (9.9)\         11 (9.7)\         8 (11.8)\         21 (8.7)\         13 (3.2)\         5 (5.7)\          2 (5.0)\          3 (2.3)\
                                  *10.4*\                             *7.9*\                               *11.2*\           *10.2*\           *10.1*\           *10.1*\           *13.3*\           10.8\             *10.3*\           *19.7*\           *16.8*\           *8.6*\
                                  *\[8.3 to 13.0)*                    *(4.4 to 14.2)*                      *(5.6 to 22.3)*   *(6.3 to 16.7)*   *(8.1 to 12.6)*   *(5.6 to 18.3)*   *(6.6 to 26.5)*   *(7.0 to 16.5)*   *(6.0 to 17.7)*   *(8.2 to 47.4)*   *(4.2 to 67.1)*   *(2.8 to 26.7)*

  Serious infections\*            27 (3.5)\                           4 (2.9)\                             2 (2.7)\          3 (1.4)\          23 (3.0)\         4 (3.5)\          1 (1.5)\          9 (3.7)\          2 (0.5)\          1 (1.1)\          0 (0.0)\          0 (0.0)\
                                  *3.6*\                              *2.8*\                               *2.8*\            *1.9*\            *3.0*\            *3.7*\            *1.6*\            *4.6*\            *1.6*\            *4.0*\            *0*               *0*
                                  *(2.5 to 5.3)*                      *(1.1 to 7.6)*                       *(0.7 to 11.1)*   *(0.6 to 5.9)*    *(2.0 to 4.5)*    *(1.4 to 9.8)*    *(0.2 to 11.6)*   *(2.4 to 8.8)*    *(0.4 to 6.3)*    *(0.6 to 28.1)*                     

  Herpes zoster\*^†^              27 (3.5)\                           8 (5.9)\                             6 (8.1)\          3 (1.4)\          32 (4.1)\         9 (8.0)\          3 (4.4)\          8 (3.3)\          3 (0.7)\          0 (0.0)\          0 (0.0)\          0 (0.0)\
                                  *3.7*\                              *5.9*\                               *9.1*\            *1.9*\            *4.3*\            *8.7*\            *5.1*\            *4.2*\            *2.4*\            *0*               *0*               *0*
                                  *(2.5 to 5.4)*                      *(3.0 to 11.8)*                      *(4.1 to 20.3)*   *(0.6 to 6.0)*    *(3.0 to 6.0)*    *(4.5 to 16.8)*   *(1.6 to 15.7)*   *(2.1 to 8.4)*    *(0.8 to 7.4)*                                        

  Malignancies (excluding NMSC)   6 (0.8)\                            0 (0.0)\                             1 (1.4)\          1 (0.5)\          9 (1.2)\          1 (0.9)\          1 (1.5)\          0 (0.0)\          0 (0.0)\          0 (0.0)\          0 (0.0)\          0 (0.0)\
                                  *0.8*\                              *0*                                  *1.4*\            *0.6*\            *1.2*\            *0.9*\            *1.6*\            *0*               *0*               *0*               *0*               *0*
                                  *(0.4*,*1.8)*                                                            *(0.2 to 9.8)*    *(0.1 to 4.5)*    *(0.6 to 2.3)*    *(0.1*,*6.5)*     *(0.2*,*11.6)*                                                                            

  NMSC                            7 (0.9)\                            1 (0.7)\                             0 (0.0)\          1 (0.5)\          6 (0.8)\          0 (0.0)\          0 (0.0)\          0 (0.0)\          1 (0.2)\          1 (1.1)\          0 (0.0)\          0 (0.0)\
                                  *0.9*\                              *0.7*\                               *0*               *0.6*\            *0.8*\            *0*               *0*               *0*               *0.8*\            *3.9*\            *0*               *0*
                                  *(0.5 to 2.0)*                      *(0.1 to 5.1)*                                         *(0.1 to 4.5)*    *(0.4 to 1.7)*                                                          *(0.1 to 5.6)*    *(0.6 to 27.9)*                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*IRs are representative up to month 24.

†All HZ events include both serious and non-serious events.

AE, adverse event; CCP, cyclic citrullinated peptide; HZ, herpes zoster; IR, incidence rate; NMSC, non-melanoma skin cancer; RF, rheumatoid factor; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

In both tofacitinib- and placebo-treated patients, generally similar IRs for discontinuations due to AEs were observed across all serotype subgroups (tofacitinib 5 mg two times a day: 7.9--11.2; tofacitinib 10 mg two times a day: 10.1--13.3; placebo: 8.6--19.7). Likewise, IRs for serious infections were generally similar across serotype subgroups (tofacitinib 5 mg two times a day: 1.9--3.6; tofacitinib 10 mg two times a day: 1.6--4.6; placebo: 0--4.0).

IRs for herpes zoster were similar between the tofacitinib 5 and 10 mg two times a day groups (1.9--9.1 and 4.2--8.7, respectively) and IRs for both tofacitinib doses were higher than for placebo (0--2.4). With respect to seropositivity, tofacitinib-treated patients who were anti-CCP-/RF+ or anti-CCP+/RF- had numerically greater IRs (5.1--9.1 and 5.9--8.7, respectively) than tofacitinib-treated patients who were anti-CCP-/RF- or anti-CCP+/RF+ (1.9--4.2 and 3.7--4.3, respectively). However 95% CIs were wide and overlapping between groups.

IRs for malignancies (excluding NMSC) were similar between the tofacitinib 5 and 10 mg two times a day groups (0--1.4 and 0--1.6, respectively). No malignancies were observed in patients receiving placebo in any serotype subgroups. IRs for NMSC were similar in both tofacitinib-treated and placebo-treated patients (tofacitinib 5 mg two times a day: 0--0.9; tofacitinib 10 mg two times a day: 0--1.6; placebo: 0--3.9). No cases of NMSC were observed in anti-CCP-/RF+ patients.

Discussion {#s4}
==========

Identifying factors that predict the likelihood of clinical response may be of benefit in treatment decision making. As elevated levels of RF and/or anti-CCP antibodies are common in patients with RA, it was hypothesised that anti-CCP and/or RF status may influence clinical response and be predictive of treatment efficacy. This posthoc analysis assessed the impact of anti-CCP and RF seropositivity on tofacitinib efficacy and safety in patients with moderately to severely active RA and an inadequate response to DMARDs, based on data pooled from five Phase III studies.

ACR20/50/70 response rates were significantly improved following treatment with tofacitinib 5 and 10 mg two times a day vs placebo across all serotype subgroups. Likewise, significant LSM changes from baseline in HAQ-DI and FACIT-F were observed among all subgroups receiving tofacitinib 5 and 10 mg two times a day vs placebo. However, some differences were observed between serotype subgroups.

ACR20/50/70 ORs demonstrated that a higher proportion of patients who were anti-CCP+/RF+ achieved ACR20/50 responses following treatment with tofacitinib 5 or 10 mg two times a day and ACR70 following treatment with tofacitinib 10 mg two times a day, compared with patients who were anti-CCP-/RF-. Furthermore, DAS28-4(ESR) remission rates following tofacitinib 5 or 10 mg two times a day appeared lower in anti-CCP- patients, regardless of RF status. Tofacitinib 10 mg two times a day was associated with a significant change from baseline (compared with placebo) in SF-36 physical functioning in anti-CCP-/RF- patients; however the effect of tofacitinib 5 mg two times a day treatment was not significant compared with placebo in this subgroup. In addition, among patients who were anti-CCP+ (regardless of RF status), significantly higher DAS28-4(ESR) remission rates were achieved with tofacitinib 5 and 10 mg two times a day compared with placebo, however no significant differences were observed in anti-CCP-/RF+ or anti-CCP-/RF- patients. DAS28-4(ESR) ORs demonstrated that a higher proportion of patients receiving tofacitinib 10 mg two times a day who were anti-CCP+/RF+ or anti-CCP+/RF- achieved DAS28-4(ESR) remission or LDA than patients who were anti-CCP-/RF-, whereas anti-CCP-/RF+patients had the same likelihood of achieving DAS28-4(ESR) remission or LDA as anti-CCP-/RF- patients.

Previous studies have assessed the influence of seropositivity on the efficacy of csDMARDs such as MTX and biologic DMARDs including abatacept, rituximab and TNFi (eg, adalimumab). A study in patients receiving abatacept or TNFi found a positive correlation between seropositivity and greater clinical response to abatacept; patients who were anti-CCP+ and RF+ were more responsive to abatacept than patients who were seropositive for only one marker, who were, in turn, more responsive than seronegative patients.[@R37] However, no correlation was observed between seropositivity for either marker and efficacy with TNFi.[@R37] Another study found that patients who were anti-CCP+ were more responsive to both abatacept and adalimumab than patients who were anti-CCP-.[@R38] Patients with the highest anti-CCP+ concentrations had greater clinical responses with abatacept than those patients with lower anti-CCP+ concentrations; no correlation was found between baseline anti-CCP antibody concentrations and adalimumab efficacy.[@R38] Other studies have also found contrasting relationships between treatment efficacy and seropositivity. In one study of anti-CCP+/RF+, anti-CCP+/RF-, anti-CCP-/RF+ and anti-CCP-/RF- patients receiving rituximab, RF+ was more indicative of response than anti-CCP+.[@R39]

With respect to safety endpoints, the incidence of AEs, SAE, serious infections and discontinuations due to AEs were similar in patients receiving tofacitinib 5 mg two times a day, tofacitinib 10 mg two times a day or placebo and across serotype subgroups. The incidence of herpes zoster was higher following tofacitinib treatment compared with placebo, which is consistent with previously reported studies of tofacitinib.[@R40] Some numerical differences in herpes zoster incidence rates were observed between serotype subgroups; however, the 95% CIs were wide and overlapping.

The analysis has a number of limitations. The data used in this study were obtained from pooled posthoc analyses of five Phase III studies. These studies were not designed to show differences based on serological status and this resulted in variations of sample sizes between subgroups. As a result, conclusions may be limited by the small patient numbers in some of the subgroups. Further prospective investigations, involving larger patient numbers, will be required in order to accurately assess potential differences in responses to tofacitinib between CCP and RF seropositive and seronegative patients with RA.

Overall, the results of this analysis of CCP and RF status in tofacitinib-treated patients with RA suggest that endpoints were not markedly influenced by seropositivity versus seronegativity. However, a higher proportion of patients who were anti-CCP+/RF+ achieved ACR20/50 responses following treatment with tofacitinib 5 or 10 mg two times a day and ACR70 following treatment with tofacitinib 10 mg two times a day, compared with patients who were anti-CCP-/RF-. Furthermore, DAS28-4(ESR) remission rates and changes from baseline in SF-36 physical functioning appeared lower in anti-CCP- patients. Further investigation is warranted to fully elucidate the relationship between seropositivity and the efficacy of tofacitinib.
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